A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01965613

Enrollment

Registered

2013-10-18

Start date

2014-01-31

Completion date

2016-12-31

Last updated

2025-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pyoderma Gangrenosum

Keywords

Pyoderma Gangrenosum

Brief summary

The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.

Detailed description

XBiotech owned bermekimab and sponsored and completed study prior to Dec 30, 2019.

Interventions

BIOLOGICALXilonix

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Age: ≥18 2. History of pyoderma gangrenosum with or without other systemic disease.

Exclusion criteria

1. Treatment with any biologicals (including intravenous immunoglobulin) or investigational agents within the last 4 weeks (or 5 half-lives, whichever is longer). 2. Treatment with corticosteroids or cyclosporine within the last 2 weeks.

Design outcomes

Primary

Measure	Time frame
Change in Physician's Wound Assessment & Patient's Global Assessment	28 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026